Key Takeaway Palantir Technologies (PLTR) is currently trading at $135.68, with analysts forecasting significant upside potential for 2026. The consensus price target ranges from 187.89 to 254.51, representing 38% to 87% upside from current levels. With the company projecting 61% revenue growth in 2026 and expanding its AI platform (AIP) across commercial and government sectors, Palantir appears p...
Key Takeaway Palantir Technologies (PLTR) is currently trading at $135.68, with analysts forecasting significant upside potential for 2026. The consensus price target ranges from 187.89 to 254.51, representing 38% to 87% upside from current levels. With the company projecting 61% revenue growth in 2026 and expanding its AI platform (AIP) across commercial and government sectors, Palantir appears positioned for continued outperformance. However, investors should consider valuation risks after the stock's massive rally. Current Market Status (February 2026) Palantir stock has experienced remarkable volatility following its AI-driven surge. After a meteoric rise throughout 2025, the stock has recently pulled back from highs above $200, presenting both opportunities and risks for investors. Metric Value Current Price $135.68 Recent High ~$200+ (Jan 2026) 52-Week Range 60.00 - 200+ Correction from High ~32% Market Sentiment Bearish Fear & Greed Index 39 (Fear) 30-Day Performance 11/30 green days (37%) Volatility 9.28% (High) 50-Day SMA $172.05 200-Day SMA $160.79 Recent Performance Palantir has delivered exceptional returns: 1-Year Performance : +144% from year-to-date lows : +144% from year-to-date lows Q4 2025 Earnings : Revenue growth accelerated to +70% : Revenue growth accelerated to +70% Operating Margins : Industry-leading 57% : Industry-leading 57% EPS Growth: 59-64% year-over-year expansion The stock's recent pullback reflects broader tech sector weakness and valuation concerns rather than fundamental deterioration. Expert Price Predictions for 2026 Wall Street analysts maintain a predominantly bullish outlook on Palantir, though price targets vary significantly based on valuation assumptions. Analyst Consensus Overview Source Price Target Upside Potential Rating 24/7 Wall St $202.50 +49.2% Buy MarketBeat Consensus $191.05 +40.8% Buy Public.com (18 Analysts) $187.89 +38.5% Buy Consensus CoinCodex $254.51 +87.6% Bullish TradersUnion $236.16 +74.1% Range: $161-$23...
格隆汇2月12日|晨星发表研报指,渣打集团首席财务官Diego De Giorgi实时离任,目前职务将由副财务总监Peter Burrill暂时接替。晨星认为是次管理层变动消息属意外负面因素,将引发市场对该行人事变动及继任安排的担忧,但指出行政总裁温拓思未表示有任何退休计划,相信渣打未来将继续专注执行Fit for Growth策略,在Peter Burrill领导下仍能实现目标,因此预期是次事件...
格隆汇2月12日|晨星发表研报指,渣打集团首席财务官Diego De Giorgi实时离任,目前职务将由副财务总监Peter Burrill暂时接替。晨星认为是次管理层变动消息属意外负面因素,将引发市场对该行人事变动及继任安排的担忧,但指出行政总裁温拓思未表示有任何退休计划,相信渣打未来将继续专注执行Fit for Growth策略,在Peter Burrill领导下仍能实现目标,因此预期是次事件对渣打营运影响有限。晨星对渣打维持营运预测及公允价值估算不变,认为港股合理价值为150港元,伦敦上市股份合理价值则为1460便士,认为其估值偏高,随着利率下行渣打的息差将受压。
Earnings Call Insights: Inspire Medical Systems (INSP) Q4 2025 Management View CEO Timothy Herbert reported that the key challenge for the business is the coding of the Inspire V procedure, explaining, "we received clarification regarding the coding that should be used for the Inspire V procedure. Currently, health care centers and physicians should bill the most recent health care policies, be it...
Earnings Call Insights: Inspire Medical Systems (INSP) Q4 2025 Management View CEO Timothy Herbert reported that the key challenge for the business is the coding of the Inspire V procedure, explaining, "we received clarification regarding the coding that should be used for the Inspire V procedure. Currently, health care centers and physicians should bill the most recent health care policies, be it a MAC or a commercial payer." Herbert estimated that "the reduction to the professional fee associated with applying the -52 modifier could range from approximately 10% to 50% of the base rate." He noted this reduction "will likely influence physicians' willingness to perform the Inspire V procedure and may limit the number of cases they choose to undertake." Herbert detailed short-term and long-term initiatives to address these reimbursement challenges and stated, "we have revised and widened our full year revenue guidance for 2026 to reflect the broad range of possible impacts that we may experience throughout the year." Herbert highlighted the clinical performance of the Inspire V system, stating, "the Inspire V system has demonstrated superiority over Inspire IV… Inspiratory overlap… has shown to be significantly improved with the Inspire V system. And the AHI in the Singapore study has demonstrated a 79.5% responder rate… far superior to the 66% responder rate demonstrated in the STAR Phase III pivotal trial in 2012." Herbert announced that the company received FDA approval for 3 Tesla MRI compatibility and is developing Inspire VI, which will include sleep detection and auto activation features. CFO Matthew Osberg stated, "Fourth quarter revenue increased 12% to $269 million and full year revenue increased 14% to $912 million, with both increases primarily driven by growth at existing centers and new center additions." Osberg added, "Fourth quarter net income per diluted share increased $3.51 to $4.66. Full year net income per diluted share increased $3.09 to $4.89."...
Droneshield is an Australia-based defense technology company that specializes in counter-drone technology. In this podcast, Motley Fool co-founder and CEO Tom Gardner and Motley Fool data engineer Beegee Alop talk with Droneshield CEO Oleg Vornik about counter-drones, the civilian and military markets, and lessons on leadership. To catch full episodes of all The Motley Fool's free podcasts, check ...
Droneshield is an Australia-based defense technology company that specializes in counter-drone technology. In this podcast, Motley Fool co-founder and CEO Tom Gardner and Motley Fool data engineer Beegee Alop talk with Droneshield CEO Oleg Vornik about counter-drones, the civilian and military markets, and lessons on leadership. To catch full episodes of all The Motley Fool's free podcasts, check out our podcast center. When you're ready to invest, check out this top 10 list of stocks to buy. A full transcript is below. This podcast was recorded on Feb. 01, 2026. Oleg Vornik: We get a lot of feedback from Ukrainians that in addition to saving their lives, it actually gives them a lot of that psychological confidence because you think about it, like for us, the buzzing annoying buzzing sound from a drone is just a bit of a nuisance. For them, it's full on trauma because you hear that thing like it's going to kill you. Mac Greer: That was Oleg Vornik, CEO of Droneshield, an Australian based defense company that specializes in counter drone technology. I'm Motley Fool producer Mac Greer. Motley Fool co founder and CEO Tom Gardner talked with Vornik about that technology and about the business of Droneshield. Tom Gardner: Hello, Fools. Very excited for this time together with the CEO of Droneshield Australian company in the counter drone Solutions business, and the CEO Oleg Vornik is with us. Thank you so much for being here, Oleg. Oleg Vornik: Thanks for having me. Tom Gardner: We also have Beegee Alop from the Motley Fool, who's going to be guiding us through some of the technical questions we're going to ask. But I think Oleg, what we want to do to start this time together is just maybe a one or two sentence description of the business because we're going to be going through the hardware and software solutions in a bit. But just a quick overview and then the history. We know you were founded in 2014. I'm curious what the first year was like in a business that nobody ...